Entropy Neurodynamics CEO to Unveil TRP-8803 Psilocin Program and Phase 2 Results at TechKnow Invest Roadshow

Entropy Neurodynamics’ Innovative IV-Infused Psilocin Platform and Therapeutic Strategy

Entropy Neurodynamics is a clinical-stage biotech company with a targeted strategy focused on proprietary psilocin formulations combined with psychotherapy. The company addresses significant unmet needs within neuropsychiatric disorders by advancing novel psychedelic drug formulations. Psilocin, the active metabolite of psilocybin, is administered in controlled clinical settings alongside psychological support to maximize therapeutic outcomes.

The lead program, TRP-8803, offers a unique IV infusion delivery method that contrasts with traditional oral psilocybin treatments. This approach aims to reduce the time to psychedelic onset, allow precise control over the intensity and duration of the psychedelic experience, and shorten overall treatment time to a commercially viable window. These advantages position TRP-8803 as a potentially superior therapeutic option for wider clinical use.

Development Journey and Clinical Experience Informing TRP-8803

Development of TRP-8803 builds on prior Phase 2a trials using oral psilocybin across neuropsychiatric indications such as Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia. These studies demonstrated clinical benefits of psilocybin-assisted psychotherapy, validating the therapeutic concept and informing the refinement of TRP-8803.

Insights from these earlier trials have guided TRP-8803’s development, enhancing its potential efficacy and expanding its applicability across multiple neuropsychiatric conditions. This evidence-based, iterative approach underscores the company’s commitment to advancing clinically validated psychedelic therapies.

Positive Phase 2 Topline Data in Treatment-Resistant Binge Eating Disorder

Entropy Neurodynamics recently announced encouraging Phase 2 topline results from Cohort 1 of its treatment-resistant Binge Eating Disorder trial, marking a key clinical milestone. These results validate the therapeutic approach in a patient group with significant unmet medical needs, specifically those resistant to conventional treatments.

The treatment-resistant BED indication is notable for investors due to the limited efficacy of existing therapies. The Phase 2 data support continued development of TRP-8803 and highlight a promising commercial opportunity. Moreover, these findings may pave the way for expanding psilocin-assisted psychotherapy into additional neuropsychiatric disorders.

Roadshow Presentation: Strategy and Commercial Potential

At the TechKnow Invest Roadshow, CEO Jason Carroll will articulate the company’s distinct positioning and the substantial commercial prospects across multiple neuropsychiatric indications. The presentation will provide a comprehensive overview of Entropy Neurodynamics, emphasizing the TRP-8803 platform beyond isolated trial results. Presentations in Melbourne and Sydney aim to engage institutional investors, fund managers, and other stakeholders interested in clinical-stage biotech opportunities.

The content will showcase clinical validation from Phase 2 outcomes alongside the commercial scalability of TRP-8803. Highlighting "significant commercial opportunity," the company signals a broad addressable market extending beyond Binge Eating Disorder. Upcoming development milestones will be detailed to offer investors insight into key clinical and regulatory catalysts.

Pharmacological Benefits of IV Psilocin Delivery Compared to Oral Psilocybin

TRP-8803’s IV delivery addresses pharmacological and practical challenges of oral psilocybin, which often has variable onset, limited dose control, and prolonged treatment durations. Intravenous infusion enables precise dosing, predictable pharmacokinetics, and modulation of psychedelic intensity and duration tailored to clinical needs.

Shortening treatment duration reduces demands on healthcare resources, lessens patient inconvenience, and enhances the commercial feasibility of psychedelic-assisted therapy at scale. Additionally, controlled dosing may improve safety by minimizing adverse experiences in vulnerable patients. These pharmacological advantages form a core part of TRP-8803’s competitive edge in the psychedelic therapeutics market.

Focus on Neuropsychiatric Disorders with High Unmet Needs

Entropy Neurodynamics targets neuropsychiatric conditions where conventional treatments often fail or produce limited results, including treatment-resistant Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia. These conditions affect large patient populations globally and are associated with significant healthcare burdens.

The company’s strategy of applying a single proprietary platform, TRP-8803, across multiple indications efficiently expands market potential. Success in one area could accelerate regulatory and clinical progress in others. This focus aligns with growing clinical, regulatory, and investor interest in psychedelic-assisted therapies as innovative treatment options.

Safety Profile and Medical Oversight in Psilocin Therapy

Entropy Neurodynamics acknowledges inherent risks associated with psilocin therapy and stresses the importance of specialist prescriber evaluation to ensure patient suitability. Potential side effects include temporary increases in blood pressure and heart rate, with some risk of psychosis in predisposed individuals, necessitating careful patient selection and monitoring.

These risks are minimized at low doses and within controlled clinical environments under direct medical supervision. TRP-8803’s IV delivery facilitates real-time dose adjustments and immediate intervention if adverse effects occur. The company’s emphasis on specialist involvement and controlled settings underscores its commitment to balancing therapeutic benefits with rigorous safety management.

Upcoming Milestones and Investor Relations Approach

The CEO’s presentation will outline forthcoming development milestones, offering investors clarity on the company’s clinical and regulatory roadmap. While specific details are not disclosed, these milestones likely include progression of the BED trial, initiation of additional studies, regulatory engagements, and advancement toward late-stage clinical development.

Participation in the TechKnow Invest Roadshow reflects Entropy Neurodynamics’ proactive investor engagement strategy, aiming to enhance visibility and understanding among Australian institutional investors. The company also provides presentation materials for broader dissemination to stakeholders unable to attend live events.

Investor Registration and Communication Preferences

Entropy Neurodynamics utilizes the Automic Group investor portal to streamline shareholder communications, encouraging investors to register at investor.automic.com.au and opt for electronic-only updates. This digital approach aligns with modern best practices, reducing costs and improving information accessibility.

The registration process is user-friendly, requiring holding numbers and postcodes to link communication preferences with shareholdings. Transitioning to electronic communications enhances timely dissemination of material updates, clinical milestones, and other investor-relevant information throughout the company’s development program.

Regulatory and Market Landscape for Psychedelic-Assisted Therapies

Entropy Neurodynamics operates amid evolving regulatory recognition of psychedelic-assisted therapies, with agencies like the FDA and EMA advancing psilocybin and MDMA programs through clinical pipelines. This favorable environment supports companies developing innovative formulations such as TRP-8803.

The commercial potential is driven by unmet needs in neuropsychiatric disorders, limited efficacy of existing treatments, and promising outcomes in treatment-resistant populations. The company’s differentiated IV psilocin platform positions it to capture value in this emerging market, though success depends on navigating regulatory pathways, clinical results, and adoption by healthcare providers and patients.